THALES
6.6.2022 08:02:10 CEST | Business Wire | Press release
A major new survey by Thales shows that two out of three Europeans citizens are looking forward to the arrival of an EU-backed Digital ID Wallet for storing their ID card, driving licence and other official documents and signed attestations on a smartphone. The results also reveal that while 27% currently use some form of official national Digital ID scheme, 45% are relying on insecure, unofficial, ‘DIY’ (do it yourself) scans and photos of their cards and documents to help prove their identity and entitlements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220605005010/en/
Digitalisation is already improving user-experience and relieving identification headaches
Starting with a pilot phase in 2023, every member state must by 2024 offer citizens a Digital ID Wallet that can be used throughout the EU. The results of the survey certainly underline the need for this pioneering European initiative aiming at offering most convenient User Experience (UX) at highest level of security. Regarding UX, 34% of people surveyed currently find it difficult to prove their identity when renewing an ID document, 30% have problems when making a high value purchase, and 29% encounter troubles when applying for financial services. However, among the 40% who face such issues, the figure falls to just 5% or below when a digital format is used.
Successful wallets will need to match highest security standards
In all but one of the countries surveyed, government emerges as the preferred provider of the EDIW. However, despite widespread public support for the idea, the results demonstrate that wallet providers must address significant security and data privacy concerns among potential users. In particular, the research shows that 65% of Europeans rate security as the most important feature in any new wallet, followed by convenience and privacy.
Results highlight different national attitudes to the EDIW
The survey uncovers differences in national attitudes. The French and the Italians are the most positive about the EDIW, with 85% and 75% respectively claiming they will use it. Enthusiasm for the EDIW is also influenced by age, and citizens’ experiences of digital wallets providers (such as Apple, Google, Samsung) and national Digital ID schemes including BankID in Sweden.
“By providing citizens with a secure and convenient means of proving their identity and entitlements via a smartphone, the EDIW will enable smooth and secure interactions between citizens, governments and private businesses. The results of our survey offer providers a better understanding of citizens’ needs, helping them to maximise adoption and use of the new wallets that will be introduced throughout the EU over the next 18 months. Thales as a leader in digital security and trustful provider of digital identities remains fully committed to address those needs thanks to field-proven wallet solutions,” said Youzec Kurp, VP Identity and Biometric Solutions at Thales.
Conducted by Thales, the survey took place in December 2021. In total, 1835 citizens from seven different EU countries provided detailed answers to an online questionnaire. The full results are now available in a new white paper: Understanding the European identity experience.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The company provides solutions, services and products that help its customers — businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
Thales Group
Market page
Download HD photos
@Thalesgroup
View source version on businesswire.com: https://www.businesswire.com/news/home/20220605005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom